Cases
Experience: Recent Representation: Assisted LYFE Capital
Novo Holdings A/S regarding a $65 million three-tranche Series A-1 Preferred Stock investment round in iECURE, Inc., a Philadelphia-based gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with significant unmet need that spun-out from The University of Pennsylvania's Gene Therapy Program.
Assisted PRA Health Sciences, a global clinical research organization, in forming a CRO joint venture with Wuxi PharmaTech to carry out Phase I-IV clinical trial services in China
h
led the later separation of the joint venture.
Assist Lyfe Capital in selling equity in Brightech International, a leading CRO that specializes in complex, value-add biostatistics, programming
clinical data management services, to Everest Clinical Research, a full-service CRO with deep expertise in biostatistics
statistical programming.
Represented VcanBio Technologies, a Chinese publicly traded pharmaceutical company in connection with a $285 million acquisition of a U.S. gene technology
engineering company, including through a lengthy CFIUS approval process.
Represented Medtronic is divesting its subsidiary Beijing Libeier Bio-engineering Institute Co., Ltd. that manufactures
sells orthopedic implant products
associated instruments for trauma
spine indications to AK Medical Holdings Limited (SEHK:1789) at the price of US$40.2 million.
Assisted a global leader in business process
technology management in acquiring majority equity interest of a BPO service provider (under VIE structure) in Shanghai.
Assisted a consulting firm in selling their equity interest in a HK company
its Shanghai WFOE to a world leading consulting firm.
Acted as the primary lawyer in China to assist a leading OEM multinational corporation in acquiring a target company's notebook PC OEM business for US$ 200 million.
Advised
assisted a leading U.S. automotive company in setting up in China an equity joint venture with a large PRC state-owned automotive company.
Represented the world's largest contract manufacturer of wire formed medical devices
components in its strategic investment in a HK medical device company
its PRC subsidiaries.
Conducted in-depth due diligence
h
led transactional documents for a research laboratory company with US$ 3 billion in annual sales for its US$ 30 million strategic investment in a PRC medical device group.
Represented a network infrastructure products
services provider in acquiring the equity interest of a PRC telecommunications equipment group for US$ 70 million.
Represented a leading NYSE-listed building products manufacturer in restructuring of its BVI
PRC subsidiaries,
in acquisition of a household appliance factory in Huizhou, China.
Assisted a digital operation platform for the life science industry from China to set up their business in the United States. The company independently develops a complete professional software product line, CRM
other SaaS products. Our legal work includes company establishment, personnel employment commercial contracts, consultation on immigration matters, office leasing,
development of privacy policies for websites
apps.
Assisted a cutting-edge technology company driven by computational design to set up a U.S. company to conduct business, including company establishment, employment contracts, website
app privacy policy development, etc.
Assisted a data
artificial intelligence high-tech company in setting up a U.S. company to conduct business. Our legal work includes the development of privacy policies for websites
apps.
Assisted a fund originating in China on investment in the United States, fund compliance, labor
employee disputes, etc.
